Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026GlobeNewsWire · 4 days ago
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026Globe News Wire · Oct 12, 2026
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to AnalystsDefense World · Oct 3, 2026
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026GlobeNewsWire · Sep 28, 2026
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’sDefense World · Sep 28, 2026
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn'sMarketBeat · Sep 27, 2026Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.05 | -$0.05 | Beat |
| May 12, 2026 | -$0.04 | -$0.05 | Miss |
| Mar 23, 2026 | -$0.02 | -$0.04 | Miss |
| Nov 10, 2025 | -$0.32 | -$0.38 | Miss |
| Aug 11, 2025 | -$0.48 | -$0.58 | Miss |
| May 12, 2025 | -$0.84 | -$0.47 | Beat |